ANTIPODES PARTNERS Ltd Invests $52,000 in Veeva Systems Inc. (NYSE:VEEV)

ANTIPODES PARTNERS Ltd purchased a new position in shares of Veeva Systems Inc. (NYSE:VEEV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 282 shares of the technology company’s stock, valued at approximately $52,000.

Other hedge funds have also modified their holdings of the company. Linscomb & Williams Inc. acquired a new stake in Veeva Systems in the 4th quarter valued at about $1,479,000. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Veeva Systems by 32.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 206,220 shares of the technology company’s stock valued at $365,000 after acquiring an additional 50,868 shares in the last quarter. APG Asset Management US Inc. purchased a new stake in shares of Veeva Systems in the fourth quarter valued at about $5,756,000. Quantum Capital Management LLC NJ boosted its holdings in shares of Veeva Systems by 9.8% in the fourth quarter. Quantum Capital Management LLC NJ now owns 329,867 shares of the technology company’s stock valued at $63,506,000 after acquiring an additional 29,525 shares in the last quarter. Finally, Eisler Capital UK Ltd. purchased a new stake in shares of Veeva Systems in the fourth quarter valued at about $1,408,000. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Veeva Systems Stock Performance

Veeva Systems stock opened at $215.45 on Friday. Veeva Systems Inc. has a 1 year low of $162.72 and a 1 year high of $236.90. The firm has a 50 day moving average price of $191.56 and a 200 day moving average price of $202.03. The company has a market cap of $34.83 billion, a price-to-earnings ratio of 63.55, a PEG ratio of 2.11 and a beta of 0.81.

Insider Activity at Veeva Systems

In other Veeva Systems news, SVP Jonathan Faddis sold 2,353 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total transaction of $470,600.00. Following the completion of the sale, the senior vice president now directly owns 9,035 shares in the company, valued at $1,807,000. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently commented on VEEV. Robert W. Baird raised their price objective on shares of Veeva Systems from $245.00 to $251.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Needham & Company LLC reiterated a “buy” rating and issued a $260.00 price objective on shares of Veeva Systems in a research note on Thursday, August 29th. Royal Bank of Canada reiterated an “outperform” rating and issued a $250.00 price objective on shares of Veeva Systems in a research note on Thursday, August 29th. BTIG Research initiated coverage on shares of Veeva Systems in a research note on Tuesday, July 9th. They issued a “buy” rating and a $240.00 price objective for the company. Finally, Stifel Nicolaus cut their target price on shares of Veeva Systems from $250.00 to $210.00 and set a “buy” rating for the company in a research report on Friday, May 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $230.57.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.